Premium
DNA Framework‐Ensembled Aptamers Enhance Fluid Stability in Circulating Tumor Cells Capture for Tumor Treatment Evaluation
Author(s) -
Chen Yirong,
Li Fan,
Zhang Shuyang,
Liu Feng,
Mao Chenzhou,
Li Min,
Jiang Jinhua,
Zhang Yueyue,
Fan Chunhai,
Zuo Xiaolei
Publication year - 2025
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.202425252
Subject(s) - aptamer , circulating tumor cell , dna , circulating tumor dna , tumor cells , cancer research , chemistry , microbiology and biotechnology , medicine , biology , cancer , biochemistry , metastasis
Abstract The recognition and binding via receptor‐ligand interactions on cell membranes often weaken in complex environments, such as whole blood samples from cancer patients, making disease diagnosis and treatment evaluation unfavorable. Constructing multivalent ligands with sufficient fluid stability in complex environments remains a challenge. Herein, we develop a tetrahedral DNA framework (TDF) ensembled multivalent aptamers (TEA n , n = 1–3) with programmable ligands size, enabling efficient capture of circulating tumor cells (CTCs) and accurate monitoring of clinical treatment progress. The precisely structured TEA n ensures the size‐matching and cooperative hybridization with epithelial cell adhesion molecule (EpCAM) on cell membrane. Compared to traditional aptamer approach, the dissociation constants (K d ) of TEA 3 exhibits ∼20‐fold growth in serum due to its precise size and rigid DNA framework. This high‐affinity interaction significantly enhances capture efficiency by improving fluid stability of TEA n and magnetic beads complex in complex environment. In addition, this CTC detection strategy is applied for clinical tumor treatment evaluation and progress monitoring in liver cancer patient samples, achieving an accuracy of ∼83.3% in classifying patients as complete or partial responses (CR/PR). Overall, this strategy will strongly promote potential clinical application of DNA framework for cancer diagnosis and disease progression monitoring.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom